Advaxis (OTC: ADXS)
Advaxis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Advaxis Company Info
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
News & Analysis
Why Range Resources, Advaxis, and StoneCo Slumped Today
Equity offerings played a big role for two of these companies.
Why Wynn Resorts, Advaxis, and Roku Jumped Today
These stocks jumped on a strong start to the second quarter.
Why Advaxis Stock Skyrocketed 13.8% Today
The small-cap biotech reported encouraging news about its prostate cancer therapy.
Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today
Despite a lack of particularly damaging news, investors are losing patience with this biotech.
Why Advaxis, Inc. Shares Are Soaring 11% Again Today
A new collaboration with Amgen, Inc. is sparking investor optimism for a second consecutive day.
Is Advaxis' Stock Now a Bargain?
The moody market wasn't kind to Advaxis last month. Here's why.
Why Advaxis, Inc. Stock Rose 19.6% in May
Despite an uneventful month, Advaxis shares rose on some bargain shopping.
Profit-Taking Clobbers Advaxis, Inc. in April Despite Positive PR
Advaxis' pipeline takes baby steps forward in April, but still remains a risky bet.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.